PMID- 8987081
OWN - NLM
STAT- MEDLINE
DCOM- 19970610
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 13
IP  - 12
DP  - 1996 Dec
TI  - Gastrointestinal uptake of biodegradable microparticles: effect of particle size.
PG  - 1838-45
AB  - PURPOSE: To investigate the effect of microparticle size on gastrointestinal 
      tissue uptake. METHODS: Biodegradable microparticles of various sizes using 
      polylactic polyglycolic acid (50:50) co-polymer (100 nm, 500 nm, 1 micron, and 10 
      microns) and bovine serum albumin as a model protein were formulated by 
      water-in-oil-in-water emulsion solvent evaporation technique. The uptake of 
      microparticles was studied in rat in situ intestinal loop model and 
      quantitatively analyzed for efficiency of uptake. RESULTS: In general, the 
      efficiency of uptake of 100 nm size particles by the intestinal tissue was 15-250 
      fold higher compared to larger size microparticles. The efficiency of uptake was 
      dependent on the type of tissue, such as Peyer's patch and non patch as well as 
      on the location of the tissue collected i.e. duodenum or ileum. Depending on the 
      size of microparticles, the Peyer's patch tissue had 2-200 fold higher uptake of 
      particles than the non-patch tissue collected from the same region of the 
      intestine. Histological evaluation of the tissue sections demonstrated that 100 
      nm particles were diffused throughout the submucosal layers while the larger size 
      nano/microparticles were predominantly localized in the epithelial lining of the 
      tissue. CONCLUSIONS: There is a microparticle size dependent exclusion phenomena 
      in the gastrointestinal mucosal tissue with 100 nm size particles showing 
      significantly greater tissue uptake. This has important implications in designing 
      of nanoparticle-based oral drug delivery systems, such as an oral vaccine system.
FAU - Desai, M P
AU  - Desai MP
AD  - University of Michigan, Division of Pediatric Cardiology, Ann Arbor 48109, USA.
FAU - Labhasetwar, V
AU  - Labhasetwar V
FAU - Amidon, G L
AU  - Amidon GL
FAU - Levy, R J
AU  - Levy RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Biocompatible Materials)
RN  - 0 (Polymers)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials/*pharmacology
MH  - Biodegradation, Environmental
MH  - Duodenum/anatomy & histology/metabolism
MH  - Ileum/anatomy & histology/metabolism
MH  - In Vitro Techniques
MH  - Intestinal Absorption/*drug effects
MH  - Intestinal Mucosa/*metabolism
MH  - *Lactic Acid
MH  - Male
MH  - *Particle Size
MH  - Peyer's Patches/anatomy & histology/metabolism
MH  - *Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymers/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NASA
OT  - Non-programmatic
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1023/a:1016085108889 [doi]
PST - ppublish
SO  - Pharm Res. 1996 Dec;13(12):1838-45. doi: 10.1023/a:1016085108889.